Foundation Fighting Blindness Retinal Degeneration Fund 13D and 13G filings for Opus Genetics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-06 5:55 pm Purchase |
2025-04-30 | 13D | Opus Genetics, Inc. IRD |
Foundation Fighting Blindness Retinal Degeneration Fund | 9,492,171 15.900% |
6,927,419 (+270.10%) |
Filing |
| 2024-10-29 5:26 pm Purchase |
2024-10-22 | 13D | Opus Genetics, Inc. IRD |
Foundation Fighting Blindness Retinal Degeneration Fund | 2,564,752 8.160% |
2,564,752 (New Position) |
Filing |